EMEA-001849-PIP02-15-M01

  • Email
  • Help

Overview

Product details for Bavencio
Invented nameBavencio
Active substance

Avelumab

Decision numberP/0361/2017
PIP numberEMEA-001849-PIP02-15-M01
Pharmaceutical form(s)Concentrate for solution for infusion
Condition(s)/indication(s)

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)

Route(s) of administrationIntravenous use
PIP applicant

Merck KGaA
Tel.: +49 6151725200
E-mail: service@merckgroup.com

Decision typePM: decision on the application for modification of an agreed PIP

Decision